KLOW Peptide Dosage: The Component Record

The short version

No validated human dosing protocol exists for the KLOW peptide blend. The canonical 80 mg vial — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — describes the as-supplied research co-formulation, not a dose schedule. Each component's literature uses different dose ranges, different species and different routes. They are not additive into a single 'KLOW dose.' This page logs what the component studies administered, so a researcher has the primary-source dose context. It does not constitute a protocol. There is no 'how much per day' recommendation on this page.

KLOW peptide dosage — the 80 mg vial composition

The most widely listed research-vial composition:

| Component | Share (mg) | Mass share | CAS | MW (Da) | |---|---|---|---|---| | GHK-Cu | 50 | ~62.5% | 89030-95-5 | 402.92 | | BPC-157 | 10 | ~12.5% | 137525-51-0 | 1419.53 | | TB-500 | 10 | ~12.5% | — | 889.02 | | KPV | 10 | ~12.5% | 67727-97-3 | 342.44 | | Total | 80 | 100% | | |

GHK-Cu dominates by mass (~62.5%). No FDA-approved or pharmacopeial combination product exists. The 80 mg/vial total is a research-market norm, not a validated pharmacological unit.

KLOW dosage — component doses from the research literature

KPV doses in key studies ^[3][9]:

• In vitro: 10 nM in cell-culture medium (human intestinal epithelial cells and T cells) — showed NF-kB suppression and cytokine reduction.
• In vivo (mouse colitis): 100 microM in drinking water (oral). Reduced DSS- and TNBS-induced colitis.
• Route studied: oral (PepT1-mediated gut delivery), cell culture.
• No validated human dose for KPV.

GHK-Cu doses in key studies ^[4][5]:

• In vitro: 1-10 nM — transcriptome modulation; procollagen induction in fibroblasts.
• Topical (clinical): formulated topical products; concentration varies by product and study.
• Route studied: topical (skin), cell culture. Injected GHK-Cu: no human clinical-trial dose.
• No validated human dose for systemic GHK-Cu.

BPC-157 doses in key studies ^[2][6][8]:

• Tendon healing (rats): 10 microg, 10 ng or 10 pg per rat IP, once daily.
• Gastric ulcer (rats): 400 ng/kg and 800 ng/kg IM or intragastric.
• IV safety pilot (humans, 2025): 10 mg day 1, 20 mg day 2, IV infusion in 250 mL saline over 1 hour. Two adult subjects; no adverse events ^[6].
• Half-life context: reported as under ~30 minutes in a rat plasma PK study — a very short clearance window.
• No FDA-approved human dose.

TB-500 (Tbeta4) doses in key studies ^[1]:

• Rat full-thickness wound model: topical application or intraperitoneal injection of native thymosin beta-4 (not the TB-500 fragment).
• In vitro keratinocyte migration: as little as 10 pg stimulated 2-3-fold migration.
• Route studied: topical, IP (native Tbeta4). Fragment (TB-500) dose data are not separately established.
• No validated human dose for the TB-500 fragment.

KLOW peptide dosage and frequency — the PK mismatch

A single co-formulated KLOW vial cannot deliver all four components at matched exposures. The pharmacokinetic mismatch is structural:

• KPV (MW 342.44 Da): small tripeptide, likely very rapid renal clearance.
• GHK-Cu (MW 402.92 Da): small tripeptide, similarly rapid. Topical bioavailability is established; systemic kinetics post-injection are not characterized.
• BPC-157 (MW 1419.53 Da): short half-life under ~30 minutes in rat plasma; longer exposure requires more frequent research dosing in rodent models.
• TB-500 (MW 889.02 Da, the fragment): pharmacokinetics not formally characterized for the fragment; native Tbeta4 has different kinetics.

The two tripeptides are likely cleared within minutes to a few hours. BPC-157 has a very short window. TB-500's fragment kinetics are unknown. A single vial dose produces four sequential, mismatched exposures — not a synchronized four-channel action. This is not a defect specific to KLOW; it is an inherent property of co-formulating peptides with different molecular weights and metabolic half-lives.

Reconstitution and stability context

The KLOW vial is supplied lyophilized (freeze-dried into a powder). Standard research handling involves reconstitution with bacteriostatic water before use. The reconstituted solution is typically refrigerated and used within a standard research window.

A theoretical compatibility consideration applies: GHK-Cu carries a chelated copper(II) ion, which can participate in redox chemistry. Co-dissolving it with three other peptides in one vial introduces a theoretical oxidation variable that has not been formally characterized for this mixture. This is a chemistry-level caution, not a documented product failure — but it is a gap in the characterization of KLOW as a combined formulation.

Subcutaneous injection is the most commonly referenced route in research-use community handling. Component literature also covers topical (GHK-Cu), oral (KPV, BPC-157) and intra-articular (BPC-157) delivery — routes that may have different absorption profiles from subcutaneous injection.